ESC 2015


Palace of Westminster, London
Photo by David Iliff

The ESC Congress 2015 took place August 29 through September 2 in London, UK.


MATRIX trial update: No clear winner

HT Staff Read Article
Published: 09/03/15

Vial of heparin

The latest results of the MATRIX trial haven’t provided any cut-and-dried answers when it comes to anticoagulation in the context of percutaneous coronary intervention (PCI), according to articles published in NEJM and data presented at the ESC Congress 2015. The trial suggested that, overall, bivalirudin and heparin produce comparable results in patients undergoing PCI. [Read Article]

Rivaroxaban appears safe, effective in the real world

HT Staff Read Article
Published: 09/02/15

Prescription medications
Photo courtesy of the CDC

Patients with atrial fibrillation (AF) who receive the anticoagulant rivaroxaban as stroke prophylaxis have low rates of major bleeding and stroke, according to real-world data from the XANTUS trial. Investigators said this finding is similar to clinical trial results with rivaroxaban and suggest the drug is safe and effective for stroke prevention in patients with AF who have a high or low risk of thromboembolic events. [Read Article]

Extending DAPT may provide benefit for some, speaker says

HT Staff Read Article
Published: 09/02/15

Drug-eluting stent

Extending dual antiplatelet therapy (DAPT) beyond the recommended 12 months after coronary stenting “should be considered” in patients with a drug-eluting stent (DES) who are at low risk for bleeding, according to investigators from the OPTIDUAL trial. The study showed that receiving DAPT—aspirin and clopidogrel—for an additional 36 months did not decrease the rate of major adverse cardiovascular and cerebrovascular events (MACCE). [Read Article]

Doc says fatal bleeding with extended DAPT is rare

HT Staff Read Article
Published: 09/01/15

Aspirin tablets
Photo by Sage Ross

Fatal bleeding is rare with extended dual antiplatelet therapy (DAPT), according to research presented at the ESC Congress 2015. The study included patients with a coronary stent who were receiving 30 months or 12 months of DAPT to prevent stent thrombosis and major cardiovascular and cerebrovascular events. The results showed that bleeding-related mortality accounted for a minority of deaths in both patient groups. [Read Article]

Score ‘modestly accurate’ for predicting thromboembolism

HT Staff Read Article
Published: 09/01/15

Image by Kevin MacKEnzie

A score used to predict the risk of thromboembolic events, ischemic stroke, and death is only modestly accurate in patients with heart failure (HF), according to researchers. They found the accuracy of the CHA2DS2-VASc score was dependent upon endpoint and follow-up time. The score proved least effective for predicting thromboembolism, and its negative predictive values (NPVs) were inferior at 5 years of follow-up compared to 1 year. [Read Article]

Research reveals potential target for stent thrombosis

HT Staff Read Article
Published: 09/01/15

Neutrophil engulfing bacteria
Image by Volker Brinkmann

Immune cells may represent an important therapeutic target for preventing stent thrombosis, according to investigators from the PRESTIGE study. The team analyzed more than 250 thrombus specimens and observed leukocyte infiltration in the context of early and late stent thrombosis. Neutrophils were the most common leukocyte detected, and eosinophils were present in thrombi from all stent types.  [Read Article]

Prolonged TV watching linked to fatal PE

HT Staff Read Article
Published: 08/31/15

Results of a large study suggest that watching television for prolonged periods may increase a person’s risk of fatal pulmonary embolism (PE). The study, which included more than 86,000 subjects, showed that watching an average of 5 or more hours of TV per day was associated with more than twice the risk of fatal PE as watching less than 2.5 hours daily. And the risk was higher among younger subjects than older ones. [Read Article]

Extra education about apixaban may be unnecessary

HT Staff Read Article
Published: 08/31/15

Apixaban (Eliquis)
Photo courtesy of Pfizer
and Bristol-Myers Squibb

An educational program designed to improve adherence to the anticoagulant apixaban proved ineffective in a phase 4 trial of patients with atrial fibrillation (AF). But that’s because adherence was high whether patients completed the program or not. This suggests current measures used to inform patients about apixaban may be sufficient to ensure treatment adherence, researchers said. They presented these findings at the ESC Congress 2015. [Read Article]


    {icon} {author} Read Article
    Published: {pubDate}